Thetis Pharmaceuticals Progressing to Clinic with a Phase 1a Trial of TP-317, an Oral Agonist of BLT1, in Healthy Subjects

First-in-human study to investigate oral TP-317, a first-in-class Resolvin E1 drug candidate that engages the LTB4-BLT1 to promote tissue repair, control inflammation, and restore immune homeostasis

ESSEX, CT – (January 16, 2024) – Thetis Pharmaceuticals LLC (“Thetis”), a biopharmaceutical company developing a first-in-class, oral small molecule Resolvin E1-based drug to treat chronic inflammatory diseases and cancer announced today that its Australian subsidiary, Thetis Pharma Pty Ltd., has received Ethics Committee approval to commence a Phase I clinical trial of TP-317 in Australia. 

The trial will examine several oral doses of TP-317 formulated as a proprietary enteric-coated tablet of Resolvin E1 (“RvE1”) given to healthy subjects. A key objective of the study is establishing the drug’s pharmacokinetic profile to enable selection of oral doses to advance into a Phase 1b study in patients with moderate-to-severe ulcerative colitis.

About Thetis Pharmaceuticals
Thetis is a clinical-stage pharmaceutical company focused on developing innovative treatments for chronic inflammatory diseases and cancer. Thetis’ lead candidate, TP-317, is a first-in-class, oral Resolvin E1 (RvE1) drug that engages the LTB4-BLT1 pathway to harness the body’s natural ability to resolve disease and restore immune homeostasis. Thetis is supported by private investors, the National Institutes of Health, and prominent philanthropies, including the Helmsley Charitable Trust, Crohn's & Colitis Foundation, and the Kenneth Rainin Foundation.

Contact Information
For more information, please visit Thetis Pharmaceuticals’ website (www.thetispharma.com) or contact us at info@thetispharma.com.